At GW Pharmaceuticals, we remain committed to ensuring our patients, healthcare partners and employees are supported during these challenging times. We are actively monitoring our supply chain and taking steps to help ensure continued supply of our products to patients. We will continue to monitor the COVID-19 situation and take steps to ensure that access and assistance for patients and healthcare partners remain consistent. If you wish to discuss more specific details please contact GW Pharmaceuticals via phone on +44 (0) 1223 238170 or via email at

If you are reporting an Adverse Event and / or a Product Complaint, and you receive a network busy signal (i.e. if all lines are busy or engaged) please continue to try your call throughout the day or, preferably report via the above email address.

Douglas Snyder

Chief Legal Officer

“Our patients come first. That’s our motto, and it drives every action, every decision, every employee — that’s what makes GW Pharmaceuticals truly unique.” 

Doug Snyder is GW’s chief legal officer, a role he has held since joining the company in July 2017. He has been providing counsel in the pharmaceutical industry and public sector for over 25 years.

As CLO, Doug is responsible for corporate and business legal counsel, intellectual property, public policy, government affairs and compliance. He also serves as GW’s company secretary.

Prior to GW, Doug was senior vice president, general counsel and secretary with responsibility for legal and compliance functions at Actelion Pharmaceuticals US, now a Janssen company. He previously served as senior vice president, general counsel and secretary at Eisai US, a human health care company, where he led legal, compliance, legislative affairs, internal audit and security. Doug was also vice president and associate general counsel for GlaxoSmithKline where he managed the legal and communications strategies for several high-profile matters involving the New York Attorney General’s Office, U.S. Department of Justice and U.S. FDA. Before joining the pharmaceutical industry, Doug was associate general counsel for the FDA, where he counseled its commissioner, appeared before the U.S. Congress in key initiatives and led the initial false claims/kickback cases against the pharmaceutical industry.

Doug earned a bachelor’s degree from Dickinson College, Carlisle, Pennsylvania, and his Juris Doctorate from Columbus School of Law at The Catholic University of America, Washington, DC.